AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:52:00Z
Is Mesoblast (MESO) The Best Australian Stock To Buy According to Hedge Funds?
Tue 03 Sep 24, 09:59 PMMesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
Fri 19 Jan 24, 04:30 PMMesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years ago
Tue 09 Jan 24, 12:35 AM5 Stocks to Ride the Santa Claus Rally
Thu 21 Dec 23, 02:38 PMMesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
Thu 23 Nov 23, 02:27 PMAvid Bioservices (CDMO) Moves 9.0% Higher: Will This Strength Last?
Wed 15 Nov 23, 09:02 AM| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Income before tax | -82.10100M | -91.58600M | -99.63000M | -87.35500M | -98.75400M |
| Minority interest | - | - | - | - | - |
| Net income | -81.88900M | -91.34700M | -98.81100M | -77.94000M | -89.79900M |
| Selling general administrative | 25.37M | 27.21M | 30.87M | 25.61M | 21.62M |
| Selling and marketing expenses | 27.73M | 30.76M | 32.72M | 25.31M | 15.36M |
| Gross profit | 7.50M | 10.21M | 7.46M | 32.16M | 16.72M |
| Reconciled depreciation | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M |
| Ebit | -69.13600M | -80.95300M | -111.86700M | -79.07200M | -83.30100M |
| Ebitda | -65.02900M | -76.57300M | -107.60300M | -75.40500M | -81.16200M |
| Depreciation and amortization | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -69.13600M | -80.95300M | -111.86700M | -79.07200M | -83.30100M |
| Other operating expenses | 76.79M | 90.78M | 115.06M | 107.56M | 97.88M |
| Interest expense | 19.44M | 16.91M | 10.71M | 13.33M | 11.33M |
| Tax provision | -0.21200M | -0.23900M | -0.81900M | -9.41500M | -8.95500M |
| Interest income | 0.83M | 0.00300M | 0.02M | 0.54M | 0.72M |
| Net interest income | -19.29100M | -17.28500M | -10.71400M | -14.71600M | -11.70400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -0.21200M | -0.23900M | -0.81900M | -9.41500M | -8.95500M |
| Total revenue | 7.50M | 10.21M | 7.46M | 32.16M | 16.72M |
| Total operating expenses | 76.79M | 90.78M | 115.06M | 107.56M | 97.88M |
| Cost of revenue | - | - | - | - | 15.36M |
| Total other income expense net | 6.48M | -10.63300M | 12.24M | -8.28300M | -15.45300M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -81.88900M | -91.34700M | -98.81100M | -77.94000M | -89.79900M |
| Net income applicable to common shares | -81.88900M | -91.34700M | -98.81100M | -77.94000M | -89.79900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Total assets | 669.41M | 662.14M | 744.72M | 733.60M | 652.12M |
| Intangible assets | 442.73M | 444.20M | 446.09M | 447.15M | 448.67M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.42M | 5.40M | 11.35M | 7.22M | 12.10M |
| Total liab | 167.58M | 165.10M | 163.32M | 184.28M | 171.06M |
| Total stockholder equity | 501.84M | 497.04M | 581.40M | 549.33M | 481.05M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 5.43M | 20.09M | 18.71M | 29.20M | 17.26M |
| Common stock | 1249.12M | 1165.31M | 1163.15M | 1051.45M | 910.40M |
| Capital stock | 1249.12M | 1165.31M | 1163.15M | 1051.45M | 910.40M |
| Retained earnings | -820.80500M | -738.91600M | -647.56900M | -548.75800M | -469.99100M |
| Other liab | 19.11M | 15.02M | 19.52M | 30.79M | 59.45M |
| Good will | 134.45M | 134.45M | 134.45M | 134.45M | 134.45M |
| Other assets | 2.33M | 1.93M | 1.72M | 3.31M | 3.32M |
| Cash | 70.92M | 60.03M | 136.88M | 129.33M | 50.43M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 41.98M | 51.37M | 94.27M | 90.14M | 44.33M |
| Current deferred revenue | 6.40M | - | - | 23.45M | - |
| Net debt | 45.58M | 46.87M | -31.38600M | -30.01400M | 30.86M |
| Short term debt | 10.01M | 8.20M | 55.97M | 35.97M | 14.01M |
| Short long term debt | 5.95M | 5.02M | 53.20M | 32.45M | 14.01M |
| Short long term debt total | 116.50M | 106.91M | 105.50M | 99.31M | 81.29M |
| Other stockholder equity | 73.52M | 1235.96M | 1228.97M | 1098.08M | 951.04M |
| Property plant equipment | 6.49M | 9.96M | 12.14M | 10.27M | 0.83M |
| Total current assets | 81.66M | 69.84M | 148.23M | 136.55M | 62.52M |
| Long term investments | 1.76M | 1.76M | 2.08M | 1.87M | 2.32M |
| Net tangible assets | -75.34500M | -81.60800M | 0.85M | -32.27500M | -102.07400M |
| Short term investments | - | - | - | - | - |
| Net receivables | 7.00M | 4.40M | 4.84M | 1.57M | 4.06M |
| Long term debt | 102.81M | 91.62M | 41.05M | 57.02M | 67.28M |
| Inventory | - | - | -4.84200M | -1.57400M | -4.06000M |
| Accounts payable | 20.14M | 23.08M | 19.60M | 24.97M | 13.06M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 73.52M | 70.65M | 65.81M | 46.63M | 40.64M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 1163.15M | 1051.45M | 910.40M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.48M | 1.93M | 1.72M | 3.31M | 3.32M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 587.76M | 592.30M | 596.49M | 597.05M | 589.59M |
| Capital lease obligations | 7.73M | 10.27M | 11.25M | 9.84M | - |
| Long term debt total | - | - | - | - | 67.28M |
| Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
| Investments | -0.19400M | -0.23200M | -1.64700M | -3.27300M | -1.00000M |
| Change to liabilities | -0.39800M | 4.78M | -5.06100M | 14.01M | -2.24300M |
| Total cashflows from investing activities | -0.19400M | -0.23200M | -1.64700M | -3.27300M | -1.00000M |
| Net borrowings | -2.65600M | -6.32700M | -2.93100M | -1.62500M | 43.57M |
| Total cash from financing activities | 74.50M | -9.87000M | 114.47M | 137.04M | 71.61M |
| Change to operating activities | 0.43M | -0.04800M | -1.61800M | -1.60700M | 17.71M |
| Net income | -81.88900M | -91.34700M | -98.81100M | -77.94000M | -89.79900M |
| Change in cash | 10.87M | -76.43400M | 7.55M | 78.90M | 12.66M |
| Begin period cash flow | 60.45M | 136.88M | 129.33M | 50.43M | 37.76M |
| End period cash flow | 71.32M | 60.45M | 136.88M | 129.33M | 50.43M |
| Total cash from operating activities | -63.26900M | -65.78200M | -106.68100M | -56.36500M | -57.79000M |
| Issuance of capital stock | 88.64M | 0.21M | 106.27M | 144.95M | 30.26M |
| Depreciation | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M |
| Other cashflows from investing activities | 0.12M | 0.12M | 0.12M | 0.12M | -0.72100M |
| Dividends paid | 0.00000M | 0.00000M | - | 0.00000M | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | -0.11800M | 0.14M | -1.73900M | 0.89M | 4.97M |
| Sale purchase of stock | - | - | - | - | 30.26M |
| Other cashflows from financing activities | -11.47700M | 48.17M | 11.13M | -5.76500M | 41.35M |
| Change to netincome | 16.98M | 16.32M | -3.71600M | 4.62M | 9.43M |
| Capital expenditures | 0.31M | 0.23M | 1.65M | 2.25M | 0.28M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -2.47200M | 4.87M | -8.41800M | 13.29M | 20.44M |
| Stock based compensation | 3.65M | 5.54M | 12.51M | 7.52M | 4.37M |
| Other non cash items | 13.54M | 11.02M | -15.40700M | 6.51M | 14.02M |
| Free cash flow | -63.58300M | -66.01400M | -108.32800M | -58.61100M | -58.06900M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MESO Mesoblast Ltd |
4.22 34.45% | 16.47 | - | 833.33 | 76.44 | 1.07 | 82.44 | -12.6414 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
55 Collins Street, Melbourne, VIC, Australia, 3000
| Name | Title | Year Born |
|---|---|---|
| Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director | 1957 |
| Dr. Eric A. Rose M.D. | Chief Medical Officer & Exec. Director | 1951 |
| Mr. Andrew Chaponnel B.Com. | Interim Chief Fin. Officer | NA |
| Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. | Chief Operating Officer | 1964 |
| Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) | Gen. Counsel & Corp. Exec. | 1968 |
| Mr. Roger D. Brown BA | Head of Spinal Orthopedic Disorders | NA |
| Mr. Michael Schuster M.B.A., MS, BSc, MBA | Head of Pharma Partnering | 1977 |
| Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA | Head of Regulatory Affairs & Quality Management | NA |
| Mr. Justin Horst B.S. | Head of Manufacturing | NA |
| Ms. Niva Sivakumar B.Com., L.L.B. | Joint Company Sec. | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...